Study design
ICH
This was a pragmatic, multicenter, randomized, single‐cycle, open‐label, parallel group prospective study, conducted at 30 enrolling sites in France between November 2018 and October 2019. The trial protocol was approved by an independent ethics committee, all patients provided written informed consent prior to initiation of any study treatment, and the study was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Conference on Harmonization guideline for Good Clinical Practice (ICH GCP) and the Declaration of Helsinki. This trial was registered with 